<DOC>
	<DOCNO>NCT00288925</DOCNO>
	<brief_summary>To evaluate safety two dose Z-360 Gemcitabine administration subject unresectable advanced pancreatic cancer order determine optimal dosage PhaseII study</brief_summary>
	<brief_title>Z-360 Unresectable Advanced Pancreatic Cancer Combination With Gemcitabine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Subjects unresectable locally advanced metastatic pancreatic cancer KPS &gt; 70 % Life expectancy least 3 month receive previous chemotherapy current indication receive previous radiotherapy current indication Currently receive chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>